Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 9/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.55 |
| ▸ | TMIGD3 | P0DMS9 | 5/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.50 |
| ▸ | CFTR | P13569 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ADK | P55263 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17802601 | 0.96 | ADORA1 (0.51) | ADORA1ADORA2ATMIGD3HPGDADORA2B | |
| SCHEMBL9792866 | 0.92 | APP (0.57) | ADORA1ADORA2ATMIGD3ADORA2BADORA3 | |
| SCHEMBL17815692 | 0.86 | APP (0.44) | ADORA1ADORA2ATMIGD3ADORA2BADORA3 | |
| SCHEMBL13729103 | 0.85 | APP (0.54) | ADORA1ADORA2ATMIGD3ADORA2BADORA3 | |
| SCHEMBL15185178 | 0.81 | CDK1 (0.39) | ADORA1ADORA2ATMIGD3ADORA2BADORA3 | |
| SCHEMBL1146235 | 0.80 | ADORA2A (0.44) | ADORA1ADORA2ATMIGD3ADORA2BADORA3 | |
| SCHEMBL17815610 | 0.80 | IP6K1 (0.48) | ADORA1ADORA2ATMIGD3ADORA2BADORA3 | |
| SCHEMBL24207973 | 0.79 | KCNH3 (0.41) | ADORA1ADORA2ATMIGD3ADORA2BADORA3 | |
| SCHEMBL17802592 | 0.78 | ADORA2A (0.44) | ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL16146635 | 0.77 | XDH (0.42) | ADORA1ADORA2ATMIGD3ADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414768-B2 | Compounds for treating cystic fibrosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-09-17 | — | — | US | disclosed |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) | 2017-12-21 | — | — | US | disclosed |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) | 2017-12-21 | — | — | US | disclosed |
| WO-2016087665-A2 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414768-B2 | Compounds for treating cystic fibrosis | CFTR, ABCB11, SLC26A4 | ADORA1 843/4885ADORA2A 2194/4885TMIGD3 4391/4885 |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | CFTR, ABCB11, SLC26A4 | ADORA1 843/4885ADORA2A 2194/4885TMIGD3 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.